- HOME
- Vol.45 No.7
- CLINICA NEUROL, 45: 514－517, 2005
- Vol.45 No.7 contents
Brief Clinical Note
Clinical features and treatment of Fisher syndrome
Masafumi Ito, M.D., Masaaki Odaka, M.D., Ph.D., Michiaki Koga, M.D., Ph.D., Koichi Hirata, M.D., Ph.D. and Nobuhiro Yuki, M.D., Ph.D.
Department of Neurology, Dokkyo University School of Medicine
To clarify the clinical features of patients with Fisher syndrome, we reviewed detailed clinical profiles and laboratory findings in 267 cases. The men: women ratio was about 3: 2, median age at onset 42 years, and the two peaks were 30-39 and 50-59. Sixty two percent of the patients had an antecedent illness with upper respiratory infectious symptoms. As initial symptoms, 63% had diplopia, 33% ataxic gait, and 17% dysesthesia of the upper and/or lower limbs. Besides ophthalmoplegia, ataxia, and areflexia, blepharoptosis (42%), internal ophthalmoplegia (35%), facial palsy (25%), and bulbar palsy (16%) were present. Limb weakness was significant in 25% and sensory impairment in 52%. CSF albuminocytological dissociation was present in 80% after the second week. Most patients were given intravenous immunoglobulin (59%). None died, and almost all had a monophasic remitting course and a generally good outcome.
(CLINICA NEUROL, 45: 514－517, 2005)
key words: Fisher syndrome, Guillain-Barrésyndrome, intravenous immunoglobulin
(Received: 26-Aug-04)
